宜宾小眼睛怎么变大(宜宾外眼角切开术) (今日更新中)

The Trump administration is promising one of the largest fireworks displays in recent memory in Washington on July Fourth. It also plans to give away as many as 300,000 face masks to those who come down to the National Mall for the festivities, although they won't be required to wear them. This is despite concerns from D.C. Mayor Muriel Bowser, who warns that the plans run counter to established health guidelines. Interior Secretary David Bernhardt on Wednesday detailed President Donald Trump's plans for Independence Day in the nation's capital and said they include a mile-long detonation of 10,000 fireworks. Trump and first lady Melania Trump plan to host events on Saturday from the White House south lawn and from the Ellipse.Additionally, military planes will conduct flyovers in a handful of major cities along the East Coast as part of this year’s July Fourth celebration. The Pentagon says roughly 1,700 service members will support a salute to the “Great Cities of the American Revolution.” The flyovers will begin in Boston and proceed to New York City, Philadelphia and Baltimore. Washington has held an Independence Day celebration for decades, featuring a parade along Constitution Avenue, a concert on the Capitol lawn with music by the National Symphony Orchestra and fireworks beginning at dusk near the Washington Monument.President Donald Trump plans to kick off Independence Day festivities with a showy display at Mount Rushmore the day before. When he speaks at the Mount Rushmore, he’ll stand before a crowd of thousands of people who won't be required to socially distance or wear masks despite the coronavirus pandemic. The event will include fighter jets thundering over the 79-year-old stone monument in South Dakota’s Black Hills and the first fireworks display there since 2009.Public health experts are warning of the risk that it could help the coronavirus to spread. And others say the fireworks will put the forest around the monument at risk to wildfires. 2003

The United States could see an increase in immigrants coming to the country after Hurricanes Irma and Harvey, according to new research from the University of Michigan.According to the study, there are multiple reasons this happens, including migrants might find it easier to flee destruction in their own country.Another reason, according to U-M economists Dean Yang and Parag Mahajan, is they are able to secure green cards or legal permanent residency through their families already established in the country."When there's a bigger stock of previous migrants to the U.S., when someone in their home country is more likely to have a connection to some sort of migrant in the U.S., then the effect of hurricanes on migration is larger," Yang said.The researchers first studied the severity of a hurricane in a given country, using data from meteorological reports to estimate actual damage.Yang and Mahajan then analyzed restricted U.S. Census data from 159 counties over 25 years to see if America saw a rise in immigration following large storms in other countries.The largest effect came from Central America and the Caribbean."These regions get hit a lot by hurricanes that cause severe damage, and there are a lot of Central American and Caribbean immigrants in the U.S., so if you're looking for someone to sponsor you, you actually have that opportunity," Mahajan said.One example of that is Hurricane Cesar hitting Nicaragua in 1996. It caused food shortages, .5 million in damage, left 100,000 people homeless and killed 42. Yang and Mahajan found that in 1996 and 1997, there was a 50 percent increase in legal permanent residencies for Nicaraguans than in 1995."Much of this increase came from immediate relatives of U.S. citizens - parents, spouses and children," Mahajan added. "Repeated, similar responses like this in the data helped us conclude that networks of U.S. citizens from sending countries provide opportunities for family members to escape severe weather events." 2007

The St. Louis Police Department is investigating one of their own after he issued a ticket to a man who honked at him.According to an interview in the Riverfront Times, Scott Smith was on his way back to work when he honked at a car stopped at a green light. Video shot by the driver and given to the RFT shows a very tense interaction.The car was an unmarked police car. When pulled over, Smith says "seriously?"The officer than replies "Seriously, is your horn stuck?" to which Smith replies "Is your brake stuck?"That's when the officer cusses at the driver asking again "Is your f-ing horn stuck?"He demands to see his driver's license.Smith says he will, but asks for what."I'll tell you what, you can either show your driver's license or you'll get a ticket and I'll tow your car and lock you up," said the officer.Once again Smith asks why he's been pulled over and the officer says it is for a traffic violation."For honking at someone who's stopped at a green light?" Smith asks. He then calls the situation "f-ing ridiculous." "Well you know what? Maybe you shouldn't be a f-ing a-hole," the officer responds.The officer issued the driver a ticket, but the city counselor's office reportedly will not prosecute it, saying they do not believe it should be pursued."The Department has launched an Internal Affairs investigation into the incident you are inquiring about. At this point, it would be premature for the Department to comment on an ongoing investigation before it concludes," a St. Louis Police spokesperson said.  1557

The Sikh community is speaking out after a Sikh Canadian minister was asked to take off his turban while going through a TSA checkpoint at Detroit Metro Airport.The incident happened in April 2017.  Navdeep Bains, Canada’s Minister of Innovation, Science and Economic Development, went through the TSA checkpoint once without any issues but was asked to go through additional screenings because of his turban."Once they realized my position, who I was, I was ultimately allowed to fly but for me this is an issue that speaks for discrimination and discrimination happens with many people," Bains said. The agency is now issuing a statement and the U.S. government is apologizing to Canada.TSA responded to the incident saying in part: 767

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

来源：资阳报